About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Y
Genome-Wide CRISPR-Cas9 Screen Identifies XPO7 as a Novel Therapeutic Target for TP53-Mutated AML
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Yuichiro Semba
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Yuichiro Semba
2 views
October 18, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Acute Myeloid Leukemia
15:38
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
2019 AML State of the Art Update: How to Treat Newly Diagnosed and S…
Feat.
S. Luger
16:27
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CAR T-Cells in AML: An Effective Therapy Requires Optimization of th…
Feat.
E. Budde
13:57
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Novel Strategies in High Risk AML: Clinical and Molecular Features
Feat.
J. Welch
16:06
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Chemotherapy-Free Approach in Relapsed/Refractory AML: Antibody-Drug…
Feat.
J. DiPersio
15:39
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
All Older AML Patients and Younger Patients with Adverse Biology Sho…
Feat.
D. Pollyea
17:20
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Youn…
Feat.
J. Lancet
15:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Use of MRD in AML: Determining Method, Acceptable Endpoint and Progn…
Feat.
P. Montesinos
14:52
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
How to Choose a FLT3 inhibitor in AML in 2019: Discussion on Midosta…
Feat.
C. Smith
15:52
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Use of Gemtuzumab in CD33 + AML: Benefit May Be Greatest in Favorabl…
Feat.
R. Walter
08:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin …
Feat.
A. Skwarska
09:44
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
The Promising Data on Efficacy of Mutant IDH1 Inhibitor Ivosidenib (…
Feat.
C. DiNardo
08:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Genome-Wide CRISPR-Cas9 Screen Identifies XPO7 as a Novel Therapeuti…
Feat.
Y. Semba